Innovative Nanobody Fusion Therapy Targeting ALB and TNFRSF18 for Advanced Allergy Management
VHH-P568 is a humanized nanobody-based fusion protein designed to target both albumin (ALB) and TNF receptor superfamily member 18 (TNFRSF18), currently under evaluation in biological testing. This advanced construct combines an antigen-binding fragment directed at TNFRSF18 with a single-domain antibody specific for ALB, joined via a molecular linker and expressed in Chinese hamster ovary (CHO) cells. The dual-specificity approach of VHH-P568 holds significant therapeutic potential for allergy by modulating immune response pathways while optimizing pharmacokinetics—capitalizing on the distinctive roles of ALB and TNFRSF18 in human immunity and inflammation.
| Candidate | VHH-P568 |
| Target | albumin (ALB) TNF receptor superfamily member 18 (TNFRSF18) |
| Modality | humanized bispecific VHH |
| Indication | Allergy |
Licensing Opportunity
VHH-P568 is actively available for out-licensing and partnership opportunities. We welcome collaborations with biotech and pharmaceutical partners seeking to advance innovative antibody fusion therapeutics in the field of allergy.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P568 |
Modality
VHH-P568 represents a next-generation modality as an antibody fusion construct. It features a single-domain variable heavy chain (VHH) that targets ALB, enzymatically linked to an antigen-binding fragment specific for TNFRSF18. Nanobodies, notable for their compact size and robust structural stability, exhibit enhanced tissue penetration and favorable pharmacokinetic profiles compared to conventional antibodies. Expressed in CHO cells to ensure scalability and reproducibility, this bifunctional format is engineered to improve in vivo half-life and bioavailability. For allergy, this modality is suited to modulate complex immune pathways with precision, enhancing therapeutic outcomes while minimizing off-target effects and supporting flexible administration regimens.
Target
VHH-P568 is designed to simultaneously target ALB and TNFRSF18. ALB, a key soluble protein, regulates plasma oncotic pressure and serves as a critical carrier for various endogenous and exogenous compounds. TNFRSF18 is a co-stimulatory receptor predominantly expressed on activated T cells and plays an essential role in immune regulation. Both ALB and TNFRSF18 are present in immune-relevant tissues and cells. In the context of allergy, targeting ALB optimizes biodistribution and serum stability of the therapeutic agent, while modulating TNFRSF18 offers immune pathway regulation. The strategic targeting of ALB and TNFRSF18 enables VHH-P568 to deliver improved efficacy and duration of therapeutic action, presenting a competitive edge for next-generation antibody therapies in immunological disorders.
Mechanism of Action
VHH-P568 leverages dual targeting by engaging both ALB and TNFRSF18. Through its anti-ALB component, VHH-P568 binds circulating albumin, enhancing serum half-life and systemic exposure. The anti-TNFRSF18 domain specifically interacts with immune effector cells, modulating co-stimulatory signaling pathways critical in allergic inflammation. This modulation can shift immune responses towards homeostasis, potentially reducing hypersensitivity and aberrant activation. As a modular nanobody platform, VHH-P568 also offers adaptability for future therapeutic formats, such as antibody-drug conjugates (ADCs) or bispecific constructs, facilitating broader clinical applications in complex immune-mediated diseases beyond allergy.
Allergy
Allergy encompasses a group of immune-mediated conditions characterized by hypersensitivity to environmental or endogenous antigens, affecting individuals globally. These disorders range from mild manifestations, such as rhinitis or urticaria, to severe, life-threatening anaphylaxis. The incidence of allergic diseases has risen worldwide, driven by genetic, environmental, and lifestyle factors. Current management strategies rely on antihistamines, corticosteroids, allergen avoidance, and, for certain indications, immunotherapy. Despite these options, many patients suffer from inadequate symptom control, treatment-related side effects, or persistent disease burden, highlighting the unmet medical need. Targeted immunomodulatory biologics like VHH-P568 offer a novel approach by precisely intervening in key immune pathways associated with allergic responses. The dual-action mechanism targeting ALB and TNFRSF18 may deliver superior pharmacokinetics and immunoregulatory benefits, supporting its potential as a transformative therapy in allergy.